Impact of Volatile Anesthetic Agents on Early Clinical Outcomes in Liver Transplantation

Richard Mangus, S. B. Kinsella, D. T. Farar, J. A. Fridell, L. T. Woolf, C. A. Kubal

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Few studies have assessed the ability of inhaled anesthetic agents to ameliorate ischemia-reperfusion injury (IRI) in liver transplantation (LT). This study compares inhaled anesthetics in early liver allograft IRI. LT recipient and organ donor data were extracted retrospectively for all LTs at a single center between 2001 and 2015. Methods: LT recipient and organ donor data were extracted retrospectively for all LTs at a single center between 2001 and 2015. The choice of primary anesthetic agent was at the discretion of the anesthesiologist. Serum alanine aminotransferase (ALT) and total bilirubin (TB) levels were measured daily in the post-transplant period as measures of early graft injury and function. Survival and clinical outcomes are reported. Results: There were 1291 primary LTs included in the analysis, with 3 primary inhaled agents: isoflurane (62%), desflurane (8%), and sevoflurane (30%). In the first 7 days post-transplant, the peak ALT level was lowest for desflurane (352), followed by sevoflurane (411) and isoflurane (481) (P =.09). All groups had similar ALT and TB by 7 days post-transplant. Graft survival for all 3 groups was statistically similar at 1, 7, and 30 days, with equivalent patient and graft survival at 1 year. Conclusions: All 3 agents had similar rates of early allograft dysfunction and renal dysfunction. Subgroup analysis of high-risk donor grafts showed no statistical difference. In conclusion, administration of desflurane or sevoflurane may provide some early hepatoprotection against IRI, but longer-term outcomes were equivalent for all agents.

Original languageEnglish (US)
Pages (from-to)1372-1377
Number of pages6
JournalTransplantation Proceedings
Volume50
Issue number5
DOIs
StatePublished - Jun 1 2018

Fingerprint

Liver Transplantation
Anesthetics
Transplants
Reperfusion Injury
Alanine Transaminase
Isoflurane
Tissue Donors
Graft Survival
Bilirubin
Allografts
Kidney
Survival
Liver
Wounds and Injuries
Serum
desflurane
sevoflurane

ASJC Scopus subject areas

  • Surgery
  • Transplantation

Cite this

Impact of Volatile Anesthetic Agents on Early Clinical Outcomes in Liver Transplantation. / Mangus, Richard; Kinsella, S. B.; Farar, D. T.; Fridell, J. A.; Woolf, L. T.; Kubal, C. A.

In: Transplantation Proceedings, Vol. 50, No. 5, 01.06.2018, p. 1372-1377.

Research output: Contribution to journalArticle

Mangus, Richard ; Kinsella, S. B. ; Farar, D. T. ; Fridell, J. A. ; Woolf, L. T. ; Kubal, C. A. / Impact of Volatile Anesthetic Agents on Early Clinical Outcomes in Liver Transplantation. In: Transplantation Proceedings. 2018 ; Vol. 50, No. 5. pp. 1372-1377.
@article{045c903dcd68420885307df7fce7158b,
title = "Impact of Volatile Anesthetic Agents on Early Clinical Outcomes in Liver Transplantation",
abstract = "Background: Few studies have assessed the ability of inhaled anesthetic agents to ameliorate ischemia-reperfusion injury (IRI) in liver transplantation (LT). This study compares inhaled anesthetics in early liver allograft IRI. LT recipient and organ donor data were extracted retrospectively for all LTs at a single center between 2001 and 2015. Methods: LT recipient and organ donor data were extracted retrospectively for all LTs at a single center between 2001 and 2015. The choice of primary anesthetic agent was at the discretion of the anesthesiologist. Serum alanine aminotransferase (ALT) and total bilirubin (TB) levels were measured daily in the post-transplant period as measures of early graft injury and function. Survival and clinical outcomes are reported. Results: There were 1291 primary LTs included in the analysis, with 3 primary inhaled agents: isoflurane (62{\%}), desflurane (8{\%}), and sevoflurane (30{\%}). In the first 7 days post-transplant, the peak ALT level was lowest for desflurane (352), followed by sevoflurane (411) and isoflurane (481) (P =.09). All groups had similar ALT and TB by 7 days post-transplant. Graft survival for all 3 groups was statistically similar at 1, 7, and 30 days, with equivalent patient and graft survival at 1 year. Conclusions: All 3 agents had similar rates of early allograft dysfunction and renal dysfunction. Subgroup analysis of high-risk donor grafts showed no statistical difference. In conclusion, administration of desflurane or sevoflurane may provide some early hepatoprotection against IRI, but longer-term outcomes were equivalent for all agents.",
author = "Richard Mangus and Kinsella, {S. B.} and Farar, {D. T.} and Fridell, {J. A.} and Woolf, {L. T.} and Kubal, {C. A.}",
year = "2018",
month = "6",
day = "1",
doi = "10.1016/j.transproceed.2018.03.001",
language = "English (US)",
volume = "50",
pages = "1372--1377",
journal = "Transplantation Proceedings",
issn = "0041-1345",
publisher = "Elsevier USA",
number = "5",

}

TY - JOUR

T1 - Impact of Volatile Anesthetic Agents on Early Clinical Outcomes in Liver Transplantation

AU - Mangus, Richard

AU - Kinsella, S. B.

AU - Farar, D. T.

AU - Fridell, J. A.

AU - Woolf, L. T.

AU - Kubal, C. A.

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Background: Few studies have assessed the ability of inhaled anesthetic agents to ameliorate ischemia-reperfusion injury (IRI) in liver transplantation (LT). This study compares inhaled anesthetics in early liver allograft IRI. LT recipient and organ donor data were extracted retrospectively for all LTs at a single center between 2001 and 2015. Methods: LT recipient and organ donor data were extracted retrospectively for all LTs at a single center between 2001 and 2015. The choice of primary anesthetic agent was at the discretion of the anesthesiologist. Serum alanine aminotransferase (ALT) and total bilirubin (TB) levels were measured daily in the post-transplant period as measures of early graft injury and function. Survival and clinical outcomes are reported. Results: There were 1291 primary LTs included in the analysis, with 3 primary inhaled agents: isoflurane (62%), desflurane (8%), and sevoflurane (30%). In the first 7 days post-transplant, the peak ALT level was lowest for desflurane (352), followed by sevoflurane (411) and isoflurane (481) (P =.09). All groups had similar ALT and TB by 7 days post-transplant. Graft survival for all 3 groups was statistically similar at 1, 7, and 30 days, with equivalent patient and graft survival at 1 year. Conclusions: All 3 agents had similar rates of early allograft dysfunction and renal dysfunction. Subgroup analysis of high-risk donor grafts showed no statistical difference. In conclusion, administration of desflurane or sevoflurane may provide some early hepatoprotection against IRI, but longer-term outcomes were equivalent for all agents.

AB - Background: Few studies have assessed the ability of inhaled anesthetic agents to ameliorate ischemia-reperfusion injury (IRI) in liver transplantation (LT). This study compares inhaled anesthetics in early liver allograft IRI. LT recipient and organ donor data were extracted retrospectively for all LTs at a single center between 2001 and 2015. Methods: LT recipient and organ donor data were extracted retrospectively for all LTs at a single center between 2001 and 2015. The choice of primary anesthetic agent was at the discretion of the anesthesiologist. Serum alanine aminotransferase (ALT) and total bilirubin (TB) levels were measured daily in the post-transplant period as measures of early graft injury and function. Survival and clinical outcomes are reported. Results: There were 1291 primary LTs included in the analysis, with 3 primary inhaled agents: isoflurane (62%), desflurane (8%), and sevoflurane (30%). In the first 7 days post-transplant, the peak ALT level was lowest for desflurane (352), followed by sevoflurane (411) and isoflurane (481) (P =.09). All groups had similar ALT and TB by 7 days post-transplant. Graft survival for all 3 groups was statistically similar at 1, 7, and 30 days, with equivalent patient and graft survival at 1 year. Conclusions: All 3 agents had similar rates of early allograft dysfunction and renal dysfunction. Subgroup analysis of high-risk donor grafts showed no statistical difference. In conclusion, administration of desflurane or sevoflurane may provide some early hepatoprotection against IRI, but longer-term outcomes were equivalent for all agents.

UR - http://www.scopus.com/inward/record.url?scp=85047844118&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047844118&partnerID=8YFLogxK

U2 - 10.1016/j.transproceed.2018.03.001

DO - 10.1016/j.transproceed.2018.03.001

M3 - Article

C2 - 29880359

AN - SCOPUS:85047844118

VL - 50

SP - 1372

EP - 1377

JO - Transplantation Proceedings

JF - Transplantation Proceedings

SN - 0041-1345

IS - 5

ER -